NYSE:NVO - Novo Nordisk A/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$81.65
▼ -0.51 (-0.62%)

This chart shows the closing price for NVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Novo Nordisk A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Novo Nordisk A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $81.65.

This chart shows the closing price for NVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 investment analysts is to hold stock in Novo Nordisk A/S. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 2 sell ratings
12/30/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
3/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 3 sell ratings
6/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 2 sell ratings
12/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 2 sell ratings
3/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
5/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
6/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/11/2021UBS GroupReiterated RatingNeutralLow
2/4/2021BarclaysReiterated RatingOverweightLow
1/20/2021Credit Suisse GroupDowngradeOutperform ➝ NeutralMedium
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
11/12/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
11/6/2020Morgan StanleyDowngradeEqual Weight ➝ UnderweightHigh
11/3/2020Societe GeneraleReiterated RatingSellLow
10/15/2020Morgan StanleyReiterated RatingEqual WeightLow
9/29/2020Berenberg BankInitiated CoverageHoldMedium
8/18/2020UBS GroupReiterated RatingNeutralLow
8/3/2020Morgan StanleyReiterated RatingEqual WeightLow
7/6/2020Bank of AmericaDowngradeBuy ➝ NeutralLow
5/18/2020Morgan StanleyReiterated RatingEqual WeightMedium
5/13/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
5/11/2020UBS GroupDowngradeBuy ➝ NeutralMedium
5/7/2020Societe GeneraleReiterated RatingSellLow
5/4/2020CowenInitiated CoverageMarket Perform$72.00Low
3/23/2020UBS GroupUpgradeNeutral ➝ BuyMedium
3/16/2020Bank of AmericaUpgradeNeutral ➝ BuyHigh
1/3/2020GuggenheimDowngradeBuy ➝ NeutralLow
11/27/2019BarclaysUpgradeEqual Weight ➝ OverweightMedium
11/22/2019Pareto SecuritiesDowngradeBuy ➝ HoldLow
11/18/2019UBS GroupDowngradeBuy ➝ NeutralLow
11/18/2019BarclaysUpgradeEqual Weight ➝ OverweightHigh
9/17/2019CitigroupUpgradeNeutral ➝ BuyLow
9/13/2019Bank of AmericaBoost Price TargetNeutral$355.00 ➝ $400.00Low
8/30/2019Jefferies Financial GroupDowngradeHold ➝ UnderperformLow
8/5/2019Pareto SecuritiesUpgradeHold ➝ BuyLow
6/20/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$52.42Medium
6/19/2019UBS GroupReiterated RatingBuy$355.00Medium
6/11/2019BarclaysUpgradeUnderweight ➝ Equal Weight$51.85Low
4/30/2019Pareto SecuritiesDowngradeBuy ➝ HoldLow
4/29/2019Credit Suisse GroupUpgradeNeutral ➝ OutperformLow
2/5/2019BarclaysReiterated RatingSellLow
2/4/2019HandelsbankenDowngradeBuy ➝ Accumulate$48.61Low
2/1/2019Morgan StanleyInitiated CoverageEqual WeightLow
1/29/2019BNP ParibasInitiated CoverageOutperformLow
12/14/2018Morgan StanleyInitiated CoverageEqual WeightLow
12/11/2018Jefferies Financial GroupReiterated RatingHold ➝ HoldMedium
12/10/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyMedium
12/2/2018UBS GroupReiterated RatingBuyMedium
11/29/2018Kepler Capital MarketsReiterated RatingHoldLow
11/26/2018HSBCReiterated RatingSellLow
11/26/2018UBS GroupReiterated RatingBuyLow
11/26/2018Pareto SecuritiesUpgradeHold ➝ BuyLow
11/19/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightLow
11/6/2018HSBCReiterated RatingSellMedium
11/2/2018CfraReiterated RatingHoldLow
10/18/2018Kepler Capital MarketsReiterated RatingHoldLow
10/8/2018GuggenheimInitiated CoverageBuy ➝ BuyMedium
10/8/2018Bank of AmericaDowngradeBuy ➝ NeutralLow
10/5/2018Pareto SecuritiesDowngradeBuy ➝ HoldLow
10/4/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
7/2/2018Sanford C. BernsteinUpgradeMarket Perform ➝ OutperformLow
1/8/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
12/29/2017JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralLow
12/6/2017Bank of AmericaUpgradeNeutral ➝ BuyMedium
12/1/2017Morgan StanleyUpgradeEqual Weight ➝ OverweightMedium
9/25/2017BNP ParibasDowngradeOutperform ➝ NeutralHigh
9/6/2017Bank of AmericaUpgradeUnderperform ➝ NeutralLow
3/7/2017BarclaysInitiated CoverageUnderweightN/A
1/3/2017JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightN/A
12/20/2016Jefferies Financial GroupReiterated RatingHoldN/A
12/6/2016UBS GroupUpgradeSell ➝ BuyN/A
12/1/2016Credit Suisse GroupReiterated RatingHoldN/A
10/31/2016DNB MarketsDowngradeBuy ➝ HoldN/A
10/31/2016CitigroupDowngradeBuy ➝ NeutralN/A
10/28/2016Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
10/16/2016Jefferies Financial GroupReiterated RatingHoldN/A
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/A
9/17/2016Bank of AmericaSet Price TargetHold$57.00N/A
9/14/2016Jefferies Financial GroupReiterated RatingHoldN/A
9/13/2016BNP ParibasUpgradeNeutral ➝ OutperformN/A
9/13/2016Pacific CrestUpgradeNeutral ➝ OutperformN/A
9/12/2016Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyN/A
9/9/2016JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralN/A
9/1/2016Morgan StanleyDowngradeOverweight ➝ Equal WeightN/A
8/8/2016Bank of AmericaDowngradeBuy ➝ NeutralN/A
8/3/2016CitigroupReiterated RatingBuyN/A
6/28/2016The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyN/A
(Data available from 6/23/2016 forward)
Novo Nordisk A/S logo
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Read More

Today's Range

Now: $81.65
Low: $81.65
High: $82.57

50 Day Range

MA: $78.49
Low: $71.51
High: $84.76

52 Week Range

Now: $81.65
Low: $63.22
High: $84.94

Volume

586,096 shs

Average Volume

978,629 shs

Market Capitalization

$192.27 billion

P/E Ratio

28.35

Dividend Yield

1.62%

Beta

0.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Novo Nordisk A/S?

The following Wall Street analysts have issued stock ratings on Novo Nordisk A/S in the last year: Bank of America Co., Barclays PLC, Berenberg Bank, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Societe Generale, and UBS Group AG.
View the latest analyst ratings for NVO.

What is the current price target for Novo Nordisk A/S?

0 Wall Street analysts have set twelve-month price targets for Novo Nordisk A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Novo Nordisk A/S in the next year.
View the latest price targets for NVO.

What is the current consensus analyst rating for Novo Nordisk A/S?

Novo Nordisk A/S currently has 2 sell ratings, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVO, but not buy more shares or sell existing shares.
View the latest ratings for NVO.

What other companies compete with Novo Nordisk A/S?

How do I contact Novo Nordisk A/S's investor relations team?

Novo Nordisk A/S's physical mailing address is Novo Alle, Bagsvaerd G7, 2880. The company's listed phone number is 45-4444-8888 and its investor relations email address is [email protected] The official website for Novo Nordisk A/S is www.novonordisk.com.